Brand Name

Compro

Generic Name
Prochlorperazine
View Brand Information
FDA approval date: November 30, 1993
Classification: Phenothiazine
Form: Suppository, Tablet

What is Compro (Prochlorperazine)?

Severe nausea and vomiting can be completely debilitating, making it impossible to function, eat or even think clearly. Whether caused by a migraine, a medical procedure or another illness, the need for relief is urgent. On a different front, managing the symptoms of a serious mental health condition like schizophrenia requires stable, effective treatment to restore clarity and control. A single, well-established medication that can help in both seemingly unrelated scenarios is Prochlorperazine.

Prochlorperazine is a prescription medication that has been used for decades. It belongs to a class of drugs known as first-generation antipsychotics, specifically a phenothiazine. While it was originally developed for psychiatric conditions, its most common use today is to control severe nausea and vomiting. As a versatile and time-tested therapy, understanding how Prochlorperazine works can help you and your doctor decide if it is the right choice for your specific needs.

What does Prochlorperazine do?

Prochlorperazine is a multi-purpose medication approved by the U.S. Food and Drug Administration (FDA) for several distinct conditions.

Its primary uses include:

  • Controlling severe nausea and vomiting: This is its most frequent application. It is highly effective at managing nausea and vomiting caused by surgery, chemotherapy, radiation therapy, migraines, and other medical conditions.
  • Treatment of schizophrenia: It helps to manage the “positive” symptoms of psychosis, such as hallucinations, delusions and disorganized thinking.
  • Short-term treatment of non-psychotic anxiety: In certain situations, it is used for a limited time to manage severe anxiety when other medications are not suitable.

For patients experiencing severe nausea, Prochlorperazine can provide rapid and profound relief, allowing them to rest, hydrate and recover. For those with psychiatric conditions, it can help to stabilize thoughts and emotions, enabling better daily functioning. Due to its side effect profile, it is now used less frequently as a long-term treatment for mental health conditions compared to newer, second-generation antipsychotics.

How does Prochlorperazine work?

Prochlorperazine works by acting on a key chemical messenger in the brain called dopamine. Dopamine has many different jobs, including regulating mood, thought processes, and the physical reflex of vomiting. Prochlorperazine is a dopamine D2 receptor antagonist, which means it blocks specific dopamine receptors in the brain.

Its function depends on where in the brain it acts:

  • For nausea and vomiting: The brain has a specific “vomiting center” known as the chemoreceptor trigger zone (CTZ). This area is rich in dopamine receptors. When these receptors are stimulated by toxins, medications or other signals, they trigger the sensation of nausea and the act of vomiting. Prochlorperazine works by blocking the dopamine receptors in the CTZ, effectively interrupting the “nausea signal” before it can take effect.
  • For schizophrenia and psychosis: The symptoms of psychosis are believed to be caused by an overactivity of dopamine in certain brain pathways that control thought and perception. By blocking dopamine receptors in these areas, Prochlorperazine helps to reduce this overactivity, which can lead to clearer thinking and a decrease in hallucinations and delusions.

By targeting this central dopamine pathway, Prochlorperazine can effectively “turn down the volume” on these different neurological processes, providing relief from both physical and psychiatric symptoms.

Prochlorperazine side effects

As a first-generation antipsychotic, Prochlorperazine has a significant side effect profile that requires careful consideration.

Common side effects often include:

  • Drowsiness, sleepiness, or sedation
  • Dizziness or light-headedness
  • Blurred vision
  • Dry mouth
  • Constipation

More serious side effects are related to its effects on movement and the central nervous system. These can include:

  • Extrapyramidal Symptoms (EPS): These are movement-related side effects, including acute dystonia (sudden, painful muscle spasms), akathisia (a feeling of inner restlessness), and parkinsonism (tremors, stiffness, and slow movement).
  • Tardive Dyskinesia (TD): A serious and potentially irreversible condition causing uncontrollable, repetitive movements of the face, tongue, or body. The risk of TD increases with long-term use.
  • Neuroleptic Malignant Syndrome (NMS): A rare but life-threatening emergency characterized by high fever, severe muscle rigidity, confusion, and autonomic instability.

Prochlorperazine has a boxed warning against use in elderly dementia patients with psychosis due to increased death risk. Avoid in children undergoing surgery and patients with severe heart or liver disease. Seek immediate medical help for high fever with muscle stiffness, uncontrollable movements, or severe allergic reactions.

Prochlorperazine dosage

Prochlorperazine comes in oral tablets, rectal suppositories (for patients who can’t keep oral medication down), and intramuscular injection (for rapid effect). Dosage and frequency vary by condition: “as needed” for nausea, regular daily schedule for psychiatric conditions.

Doctors primarily monitor treatment effectiveness and side effects, especially movement issues. Long-term use may require periodic check-ups, including blood and liver tests. Due to drowsiness and dizziness, avoid driving or operating heavy machinery until you understand the medication’s effects.

Does Prochlorperazine have a generic version?

Yes, Prochlorperazine is a long-standing medication and is widely available as a generic. The most common brand names in the past were Compazine and Compro, but today, the generic version is almost exclusively prescribed. The availability of a generic makes this an effective and very affordable treatment option.

Conclusion

Prochlorperazine is a powerful and effective medication that has earned its place as a reliable treatment for severe nausea and vomiting and as an option for certain psychiatric conditions. Its ability to block dopamine signals in the brain makes it highly effective at providing relief.

However, its benefits must be weighed against a significant risk of side effects, particularly movement disorders and the serious risks outlined in its boxed warning. For this reason, it must be used with caution and under the close supervision of a healthcare provider, especially for long-term treatment. When used appropriately, Prochlorperazine can be an invaluable tool for restoring comfort and stability.

References

  1. National Institutes of Health. (2018). Prochlorperazine. MedlinePlus. https://medlineplus.gov/druginfo/meds/a682116.html
  2. Mayo Clinic. (2024). Prochlorperazine (Oral Route, Rectal Route). https://www.mayoclinic.org/drugs-supplements/prochlorperazine-oral-route-rectal-route/side-effects/drg-20072288
  3. U.S. Food and Drug Administration (FDA). (2018). COMPAZINE (prochlorperazine) Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/010580s102,011322s074lbl.pdf

Top Global Experts

There are no experts for this drug

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

There is no latest advances for this treatment

Brand Information

Compro (PROCHLORPERAZINE)
1DESCRIPTION
Prochlorperazine, a phenothiazine derivative, is designated chemically as 2-Chloro -10-[3-(4-methyl-1-piperazinyl)propyl]phenothiazine with the following structural formula:
chemical-structure
Each suppository, for rectal administration, contains 25 mg of prochlorperazine; with glycerin, glyceryl monopalmitate, glyceryl monostearate, hydrogenated coconut oil fatty acids and hydrogenated palm kernel oil fatty acids.
2CLINICAL PHARMACOLOGY
Prochlorperazine is a propylpiperazine derivative of phenothiazine. Like other phenothiazines, it exerts an antiemetic effect through a depressant action on the chemoreceptor trigger zone.
3INDICATIONS AND USAGE
Prochlorperazine 25 mg suppositories are indicated in the control of severe nausea and vomiting in adults.
4CONTRAINDICATIONS
Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.).
Do not use in pediatric surgery.
Do not use in children under 2 years of age or under 20 lbs. Do not use in children for conditions for which dosage has not been established.
5ADVERSE REACTIONS
Drowsiness, dizziness, amenorrhea, blurred vision, skin reactions and hypotension may occur.
Cholestatic jaundice has occurred. If fever with grippe-like symptoms occurs, appropriate liver studies should be conducted. If tests indicate an abnormality, stop treatment. There have been a few observations of fatty changes in the livers of patients who have died while receiving the drug. No causal relationship has been established.
Leukopenia and agranulocytosis have occurred. Warn patients to report the sudden appearance of sore throat or other signs of infection. If white blood cell and differential counts indicate leukocyte depression, stop treatment and start antibiotic and other suitable therapy.
5.1Neuromuscular (Extrapyramidal) Reactions
These symptoms are seen in a significant number of hospitalized mental patients. They may be characterized by motor restlessness, be of the dystonic type, or they may resemble parkinsonism.
Depending on the severity of symptoms, dosage should be reduced or discontinued. If therapy is reinstituted, it should be at a lower dosage. Should these symptoms occur in children or pregnant patients, the drug should be stopped and not reinstituted. In most cases barbiturates by suitable route of administration will suffice. (Or, injectable diphenhydramine may be useful.) In more severe cases, the administration of an anti-parkinsonism agent, except levodopa (see
5.1.1Motor Restlessness:
Symptoms may include agitation or jitteriness and sometimes insomnia. These symptoms often disappear spontaneously. At times these symptoms may be similar to the original neurotic or psychotic symptoms. Dosage should not be increased until these side effects have subsided.
If these symptoms become too troublesome, they can usually be controlled by a reduction of dosage or change of drug. Treatment with anti-parkinsonian agents, benzodiazepines or propranolol may be helpful.
5.1.2Pseudo-parkinsonism:
Symptoms may include: mask-like facies; drooling; tremors; pillrolling motion; cogwheel rigidity; and shuffling gait. Reassurance and sedation are important. In most cases these symptoms are readily controlled when an anti-parkinsonism agent is administered concomitantly. Anti-parkinsonism agents should be used only when required. Generally, therapy of a few weeks to 2 or 3 months will suffice. After this time patients should be evaluated to determine their need for continued treatment. (Note: Levodopa has not been found effective in pseudo-parkinsonism.) Occasionally it is necessary to lower the dosage of prochlorperazine or to discontinue the drug.
5.1.3Tardive Dyskinesia:
As with all antipsychotic agents, tardive dyskinesia may appear in some patients on long-term therapy or may appear after drug therapy has been discontinued. The syndrome can also develop, although much less frequently, after relatively brief treatment periods at low doses. This syndrome appears in all age groups. Although its prevalence appears to be highest among elderly patients, especially elderly women, it is impossible to rely upon prevalence estimates to predict at the inception of neuroleptic treatment which patients are likely to develop the syndrome. The symptoms are persistent and in some patients appear to be irreversible. The syndrome is characterized by rhythmical involuntary movements of the tongue, face, mouth or jaw (e.g., protrusion of tongue, puffing of cheeks, puckering of mouth, chewing movements). Sometimes these may be accompanied by involuntary movements of extremities. In rare instances, these involuntary movements of the extremities are the only manifestations of tardive dyskinesia. A variant of tardive dyskinesia, tardive dystonia, has also been described.
There is no known effective treatment for tardive dyskinesia; anti-parkinsonism agents do not alleviate the symptoms of this syndrome. It is suggested that all antipsychotic agents be discontinued if these symptoms appear.
Should it be necessary to reinstitute treatment, or increase the dosage of the agent, or switch to a different antipsychotic agent, the syndrome may be masked.
It has been reported that fine vermicular movements of the tongue may be an early sign of the syndrome and if the medication is stopped at that time the syndrome may not develop.
5.2Adverse Reactions Reported with Prochlorperazine or Other Phenothiazine Derivatives:
Adverse reactions with different phenothiazines vary in type, frequency and mechanism of occurrence, i.e., some are dose-related, while others involve individual patient sensitivity. Some adverse reactions may be more likely to occur, or occur with greater intensity, in patients with special medical problems, e.g., patients with mitral insufficiency or pheochromocytoma have experienced severe hypotension following recommended doses of certain phenothiazines.
Not all of the following adverse reactions have been observed with every phenothiazine derivative, but they have been reported with 1 or more and should be borne in mind when drugs of this class are administered: extrapyramidal symptoms (opisthotonos, oculogyric crisis, hyperreflexia, dystonia, akathisia, dyskinesia, parkinsonism) some of which have lasted months and even years- particularly in elderly patients with previous brain damage; grand mal and petit mal convulsions, particularly in patients with EEG abnormalities or history of such disorders; altered cerebrospinal fluid proteins; cerebral edema; intensification and prolongation of the action of central nervous system depressants (opiates, analgesics, antihistamines, barbiturates, alcohol), atropine, heat, organophosphorus insecticides; autonomic reactions (dryness of the mouth, nasal congestion, headache, nausea, constipation, obstipation, adynamic ileus, ejaculatory disorders/impotence, priapism, atonic colon, urinary retention, miosis and mydriasis); reactivation of psychotic processes, catatonic-like states; hypotension (sometimes fatal); cardiac arrest; blood dyscrasias (pancytopenia, thrombocytopenic purpura, leukopenia, agranulocytosis, eosinophilia, hemolytic anemia, aplastic anemia); liver damage (jaundice, biliary stasis); endocrine disturbances (hyperglycemia, hypoglycemia, glycosuria, lactation, galactorrhea, gynecomastia, menstrual irregularities, false-positive pregnancy tests); skin disorders (photosensitivity, itching, erythema, urticaria, eczema up to exfoliative dermatitis); other allergic reactions (asthma, laryngeal edema, angioneurotic edema, anaphylactoid reactions); peripheral edema; reversed epinephrine effect; hyperpyrexia; mild fever after large I.M. doses; increased appetite; increased weight; a systemic lupus erythematosus-like syndrome; pigmentary retinopathy; with prolonged administration of substantial doses, skin pigmentation, epithelial keratopathy, and lenticular and corneal deposits.
EKG changes-particularly nonspecific, usually reversible Q and T wave distortions-have been observed in some patients receiving phenothiazine tranquilizers.
Although phenothiazines cause neither psychic nor physical dependence, sudden discontinuance in long-term psychiatric patients may cause temporary symptoms, e.g., nausea and vomiting, dizziness, tremulousness.
Note:There have been occasional reports of sudden death in patients receiving phenothiazines. In some cases, the cause appeared to be cardiac arrest or asphyxia due to failure of the cough reflex.
6OVERDOSAGE
(See also
7HOW SUPPLIED
Compro
2's - NDC 55289-119-02, 6's NDC 55289-119-06
8Package/Label Display Panel
Rx Only
Prochlorperazine Suppositories, USP
25 mg
FOR RECTAL USE ONLY
ADULT SIZE
NOT FOR USE IN CHILDREN
55289119 Label
The following image is a placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation.
serialization-template.jpg